367 related articles for article (PubMed ID: 32814115)
21. Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer.
Gutiérrez JR; Salgado ARM; Arias MÁ; San-Juan-Vergara H; Rada WR; Gómez CMM
Curr Med Chem; 2022; 29(9):1503-1542. PubMed ID: 34963430
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic-based therapies in cancer: progress to date.
Song SH; Han SW; Bang YJ
Drugs; 2011 Dec; 71(18):2391-403. PubMed ID: 22141383
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy.
Myasoedova VA; Sukhorukov V; Grechko AV; Zhang D; Romanenko E; Orekhov V; Orekhov AN
Curr Pharm Des; 2019; 25(6):635-641. PubMed ID: 30950345
[TBL] [Abstract][Full Text] [Related]
24. Targeting the histone orthography of cancer: drugs for writers, erasers and readers.
Simó-Riudalbas L; Esteller M
Br J Pharmacol; 2015 Jun; 172(11):2716-32. PubMed ID: 25039449
[TBL] [Abstract][Full Text] [Related]
25. Chemical Tools with Fluorescence Switches for Verifying Epigenetic Modifications.
Hori Y; Kikuchi K
Acc Chem Res; 2019 Oct; 52(10):2849-2857. PubMed ID: 31577127
[TBL] [Abstract][Full Text] [Related]
26. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
27. Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics.
Li Y; Li Z; Zhu WG
Curr Med Chem; 2019; 26(8):1328-1350. PubMed ID: 28933282
[TBL] [Abstract][Full Text] [Related]
28. [Development of novel epigenetic molecular-targeting agents].
Sowa Y; Sakai T
Nihon Rinsho; 2015 Aug; 73(8):1263-7. PubMed ID: 26281676
[TBL] [Abstract][Full Text] [Related]
29. Targeting Histone Onco- Modifications Using Plant-Derived Products.
Illam SP; Kandiyil SP; Raghavamenon AC
Curr Drug Targets; 2021; 22(11):1317-1331. PubMed ID: 33461463
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation, histone acetylation and methylation of epigenetic modifications as a therapeutic approach for cancers.
Yen CY; Huang HW; Shu CW; Hou MF; Yuan SS; Wang HR; Chang YT; Farooqi AA; Tang JY; Chang HW
Cancer Lett; 2016 Apr; 373(2):185-92. PubMed ID: 26808576
[TBL] [Abstract][Full Text] [Related]
31. New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics.
Duan YT; Sangani CB; Liu W; Soni KV; Yao Y
Curr Top Med Chem; 2019; 19(12):972-994. PubMed ID: 31161992
[TBL] [Abstract][Full Text] [Related]
32. New therapeutic targets in cancer: the epigenetic connection.
Herranz M; Esteller M
Clin Transl Oncol; 2006 Apr; 8(4):242-9. PubMed ID: 16648099
[TBL] [Abstract][Full Text] [Related]
33. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
[TBL] [Abstract][Full Text] [Related]
34. Reversing aberrant methylation patterns in cancer.
Poke FS; Qadi A; Holloway AF
Curr Med Chem; 2010; 17(13):1246-54. PubMed ID: 20166939
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic modifications as therapeutic targets.
Kelly TK; De Carvalho DD; Jones PA
Nat Biotechnol; 2010 Oct; 28(10):1069-78. PubMed ID: 20944599
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy.
Biswas S; Rao CM
Eur J Pharmacol; 2018 Oct; 837():8-24. PubMed ID: 30125562
[TBL] [Abstract][Full Text] [Related]
37. Histone Modifications in Alzheimer's Disease.
Santana DA; Smith MAC; Chen ES
Genes (Basel); 2023 Jan; 14(2):. PubMed ID: 36833274
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic modifications in prostate cancer.
Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
[TBL] [Abstract][Full Text] [Related]
40. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
Perez-Plasencia C; Duenas-Gonzalez A
Mol Cancer; 2006 Jul; 5():27. PubMed ID: 16831224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
